» Articles » PMID: 20681003

A Basic Study Design for Expedited Safety Signal Evaluation Based on Electronic Healthcare Data

Overview
Publisher Wiley
Date 2010 Aug 4
PMID 20681003
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Active drug safety monitoring based on longitudinal electronic healthcare databases (a Sentinel System), as outlined in recent FDA-commissioned reports, consists of several interlocked processes, including signal generation, signal strengthening, and signal evaluation. Once a signal of a potential drug safety issue is generated, signal strengthening and signal evaluation have to follow in short sequence in order to quickly provide as much information about the triggering drug-event association as possible. This paper proposes a basic study design based on the incident user cohort design for expedited signal evaluation in longitudinal healthcare databases. It will not resolve all methodological issues nor will it fit all study questions arising within the framework of a Sentinel System. It should rather be seen as a guidance that will fit the majority of situations and serve as a starting point for adaptations to specific studies. Such an approach will expedite and structure the process of study development and highlight specific assumptions, which is particularly valuable in a Sentinel System where signals are by definition preliminary and evaluation of signals is time critical.

Citing Articles

Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.

Shin H, Paik J, Everett B, DiCesare E, Alix C, Glynn R JAMA Intern Med. 2025; 185(3):302-313.

PMID: 39836397 PMC: 11877166. DOI: 10.1001/jamainternmed.2024.7357.


Association of higher potency statin use with risk of osteoporosis and fractures in patients with stroke in a Korean nationwide cohort study.

Jeong J, Noh Y, Cho S, Hsieh C, Cho Y, Shin J Sci Rep. 2024; 14(1):30825.

PMID: 39730536 PMC: 11680841. DOI: 10.1038/s41598-024-81628-z.


Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data.

Birck M, Lukusa L, Choquette D, Boire G, Maksymowych W, Singh H BMC Rheumatol. 2024; 8(1):47.

PMID: 39343928 PMC: 11441163. DOI: 10.1186/s41927-024-00415-5.


From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population.

Delea T, Ma Q, Kroog G, Ge W, Moynahan A, Sabater Anaya N Oncol Ther. 2024; 12(3):565-583.

PMID: 39097860 PMC: 11333644. DOI: 10.1007/s40487-024-00291-6.


A future of data-rich pharmacoepidemiology studies: transitioning to large-scale linked electronic health record + claims data.

Schneeweiss S, Desai R, Ball R Am J Epidemiol. 2024; 194(2):315-321.

PMID: 39013780 PMC: 11815500. DOI: 10.1093/aje/kwae226.


References
1.
Suissa S . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2007; 167(4):492-9. DOI: 10.1093/aje/kwm324. View

2.
Lunt M, Solomon D, Rothman K, Glynn R, Hyrich K, Symmons D . Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol. 2009; 169(7):909-17. PMC: 2656533. DOI: 10.1093/aje/kwn391. View

3.
Brookhart M, Schneeweiss S, Rothman K, Glynn R, Avorn J, Sturmer T . Variable selection for propensity score models. Am J Epidemiol. 2006; 163(12):1149-56. PMC: 1513192. DOI: 10.1093/aje/kwj149. View

4.
Kiyota Y, Schneeweiss S, Glynn R, Cannuscio C, Avorn J, Solomon D . Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004; 148(1):99-104. DOI: 10.1016/j.ahj.2004.02.013. View

5.
Lagakos S . The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006; 354(16):1667-9. DOI: 10.1056/NEJMp068070. View